/MCK
MCK Stock - McKesson Corporation
Healthcare|Medical - DistributionNYSE
$820.25+1.20%
+$9.69 (+1.20%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.66
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).80
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+15.2%upside
Target: $944.93
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MCK
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$812.05 – $828.45
TARGET (TP)$945.00
STOP LOSS$754.63
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.38
52W High$895.58
52W Low$565.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $359.05B | $308.95B | $276.71B | $263.97B | $238.23B |
| Gross Profit | $12.48B | $12.20B | $11.87B | $12.65B | $11.58B |
| Gross Margin | 3.5% | 3.9% | 4.3% | 4.8% | 4.9% |
| Operating Income | $4.37B | $3.93B | $4.45B | $2.72B | $3.51B |
| Net Income | $3.29B | $3.00B | $3.56B | $1.11B | $-4,539,000,000 |
| Net Margin | 0.9% | 1.0% | 1.3% | 0.4% | -1.9% |
| EPS | $25.86 | $22.54 | $25.23 | $7.31 | $-27.02 |
Company Overview
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
50%
Hold / Neutral
5
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish5 Neutral/Bearish
Price Targets
$589
Average Target
↓ 28.2% Downside
Now
$378
Low
$589
Average
$960
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 9th 2025 | Barclays | Initiation | Overweight | $960 |
| December 4th 2024 | Mizuho | Resumed | Neutral | $630 |
| November 7th 2024 | Robert W. Baird | Upgrade | Outperform | $688← $531 |
| September 24th 2024 | Robert W. Baird | Downgrade | Neutral | $531← $603 |
| September 5th 2024 | Leerink Partners | Reiterated | Outperform | $665← $670 |
| August 8th 2024 | Mizuho | Reiterated | Neutral | $570← $540 |
| February 26th 2024 | Leerink Partners | Initiation | Outperform | $600 |
| January 3rd 2024 | Barclays | Initiation | Overweight | $537 |
| December 14th 2023 | Wells Fargo | Initiation | Equal Weight | $502 |
| March 31st 2023 | Citigroup | Initiation | Buy | $420 |
| August 22nd 2022 | Morgan Stanley | Resumed | Overweight | - |
| July 6th 2022 | Argus | Downgrade | Hold | - |
| June 7th 2022 | Deutsche Bank | Upgrade | Buy | $378← $343 |
Earnings History & Surprises
MCKBeat Rate
78%
Last 18 quarters
Avg Surprise
+8.3%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$9.86
Q4 2025
EPS Surprise History
Q1 24
+9.9%
$7.74vs$7.04
Q2 24
-2.5%
$6.18vs$6.34
Q3 24
+9.3%
$7.88vs$7.21
Q4 24
+2.8%
$7.07vs$6.88
Q1 25
-6.6%
$8.03vs$8.60
Q2 25
+3.0%
$10.12vs$9.83
Q3 25
+1.5%
$8.26vs$8.14
Q4 25
+9.2%
$9.86vs$9.03
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 4, 2026 | $9.19 | — | — | — |
Q4 2025 | Nov 5, 2025 | $9.03 | $9.86 | +9.2% | ✓ BEAT |
Q3 2025 | Aug 6, 2025 | $8.14 | $8.26 | +1.5% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $9.83 | $10.12 | +3.0% | ✓ BEAT |
Q1 2025 | Feb 5, 2025 | $8.60 | $8.03 | -6.6% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $6.88 | $7.07 | +2.8% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $7.21 | $7.88 | +9.3% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $6.34 | $6.18 | -2.5% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $7.04 | $7.74 | +9.9% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $6.15 | $6.23 | +1.3% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $5.87 | $7.27 | +23.9% | ✓ BEAT |
Q2 2023 | May 8, 2023 | $7.17 | $7.19 | +0.3% | ✓ BEAT |
Q1 2023 | Feb 1, 2023 | $6.35 | $6.90 | +8.7% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $6.09 | $6.06 | -0.5% | ✗ MISS |
Q3 2022 | Aug 3, 2022 | $5.28 | $5.83 | +10.4% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $6.06 | $5.83 | -3.8% | ✗ MISS |
Q1 2022 | Feb 2, 2022 | $5.38 | $6.15 | +14.3% | ✓ BEAT |
Q4 2021 | Nov 1, 2021 | $4.67 | $6.15 | +31.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $4.09 | $5.56 | +35.9% | ✓ BEAT |
Latest News
Barclays Initiates Coverage On McKesson with Overweight Rating, Announces Price Target of $960
📈 PositiveBenzinga•Dec 9, 2025, 03:04 PM•Also:
CNBC Halftime Report Final Trades: Freeport-McMoRan, Cisco Systems, Teradyne, McKesson
➖ NeutralBenzinga•Nov 19, 2025, 06:01 PM•Also: , ,
Wells Fargo Maintains Equal-Weight on McKesson, Raises Price Target to $914
📈 PositiveBenzinga•Nov 10, 2025, 02:24 PM
UBS Maintains Buy on McKesson, Raises Price Target to $980
📈 PositiveBenzinga•Nov 6, 2025, 05:43 PM
Baird Maintains Outperform on McKesson, Raises Price Target to $927
📈 PositiveBenzinga•Nov 6, 2025, 05:38 PM
Morgan Stanley Maintains Overweight on McKesson, Raises Price Target to $916
📈 PositiveBenzinga•Nov 6, 2025, 03:01 PM
McKesson Raises FY2026 Adj EPS Guidance from $38.05-$38.55 to $38.35-$38.85 vs $38.33 Est
📈 PositiveBenzinga•Nov 5, 2025, 09:24 PM
McKesson Q2 Adj. EPS $9.86 Beats $9.04 Estimate, Sales $103.150B Miss $104.134B Estimate
➖ NeutralBenzinga•Nov 5, 2025, 09:23 PM
UBS Maintains Buy on McKesson, Raises Price Target to $920
📈 PositiveBenzinga•Oct 27, 2025, 06:00 PM
Citius Oncology Secures McKesson As Authorized U.S. Distributor For LYMPHIR Ahead Of Q4 2025 Launch
📈 PositiveBenzinga•Oct 20, 2025, 12:39 PM•Also:
Seeking Alpha's healthcare quant picks ahead of Q3 earnings: McKesson, Incyte top-rated stocks
📈 PositiveSeeking Alpha•Oct 14, 2025, 01:35 PM•Also:
Jefferies Maintains Buy on McKesson, Raises Price Target to $900
📈 PositiveBenzinga•Oct 14, 2025, 12:20 PM•Also:
McKesson shares are trading higher after JPMorgan maintained an Overweight rating on the stock and raised its price target from $821 to $853.
📈 PositiveBenzinga•Sep 26, 2025, 04:31 PM
JP Morgan Maintains Overweight on McKesson, Raises Price Target to $853
📈 PositiveBenzinga•Sep 26, 2025, 01:10 PM•Also:
Evercore ISI Group Maintains Outperform on McKesson, Raises Price Target to $825
📈 PositiveBenzinga•Sep 24, 2025, 04:36 PM
TD Cowen Maintains Buy on McKesson, Raises Price Target to $864
📈 PositiveBenzinga•Sep 24, 2025, 04:07 PM
Citigroup Maintains Buy on McKesson, Raises Price Target to $860
📈 PositiveBenzinga•Sep 24, 2025, 02:15 PM•Also:
Mizuho Maintains Neutral on McKesson, Raises Price Target to $770
➖ NeutralBenzinga•Sep 24, 2025, 02:06 PM
Morgan Stanley Maintains Overweight on McKesson, Raises Price Target to $857
📈 PositiveBenzinga•Sep 24, 2025, 01:20 PM
Deutsche Bank Maintains Buy on McKesson, Raises Price Target to $856
📈 PositiveBenzinga•Sep 24, 2025, 12:59 PM•Also:
Frequently Asked Questions about MCK
What is MCK's current stock price?
McKesson Corporation (MCK) is currently trading at $820.25 per share. The stock has moved +1.20% today.
What is the analyst price target for MCK?
The average analyst price target for MCK is $945.00, based on 1 analyst.
What sector is McKesson Corporation in?
McKesson Corporation operates in the Healthcare sector, specifically within the Medical - Distribution industry. The company is traded on the NYSE exchange.
What is MCK's market cap?
McKesson Corporation has a market capitalization of $102.53 billion, making it a large-cap company.
Does MCK pay dividends?
No, McKesson Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBMY
Bristol-Myers Squibb Company
$54.19
Mkt Cap: $110.3B
CAH
Cardinal Health, Inc.
$202.95
Mkt Cap: $48.2B
COR
Cencora, Inc.
$340.93
Mkt Cap: $66.1B
CVS
CVS Health Corporation
$77.72
Mkt Cap: $98.7B
GSK
GSK plc
$48.61
Mkt Cap: $98.8B
HCA
HCA Healthcare, Inc.
$472.98
Mkt Cap: $114.8B
MDT
Medtronic plc
$98.63
Mkt Cap: $126.5B
SNY
Sanofi
$48.18
Mkt Cap: $117.4B
SYK
Stryker Corporation
$355.20
Mkt Cap: $135.8B
VRTX
Vertex Pharmaceuticals Incorporated
$456.20
Mkt Cap: $117.1B
Explore stocks similar to MCK for comparison